At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles, will show data from one of his ongoing studies where highly sensitized patients are desensitized and treated with Hansa Medical’s lead candidate drug IdeS prior to transplantation. Data will be shown from a patient with a PRA level of 100% who was treated and transplanted successfully in July this year. The investigator-sponsored clinical phase II study, which was initiated and led by Dr. Jordan, is an open-label study to assess the safety and efficacy of IdeS in eliminating donor specific antibodies and thus prevent antibody-mediated rejection in highly sensitized patients. The study, in which IdeS is added to Dr. Jordan’s standard protocols for sensitized patients, will include up to 20 highly sensitized patients on the UNOS (United Network for Organ Sharing) waiting list. All included patients will undergo kidney transplantation and be followed up for 6 months post transplantation. “Data that we have seen in this patient is amazing, and could potentially revolutionize the whole area of transplantation, especially in sensitized patients”, said Dr. Jordan. ““It is promising to see that IdeS is so effective in removing HLA antibodies also in this difficult group of higly sensitized patients”, commented Lena Winstedt, Clinical Research Director. The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on November 13, 2015, at 08.45 CET. For further information, please contact: Hansa Medical AB Lena Winstedt, Ph.D, Clinical Research Director Mobil: 46 76-858 15 06 E-mail: lena.winstedt@hansamedical.com Göran Arvidson, CEO Mobile: 46 70-390 85 30 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About Dr. Stanley Jordan Dr. Stanley Jordan is a Director of Kidney Transplantation and Transplant Immunology, Kidney and Pancreas Transplant Center and Director of Division of Pediatric and Adult Nephrology at Cedars Sinai Medical Center, Los Angeles, USA. Dr. Jordan's focus is on immunology and transplantation. He has performed extensive research funded by dozens of research grants and awards, including National Institutes of Health controlled clinical trials in kidney transplantation. Dr. Jordan has written hundreds of articles in scientific journals and authored about two dozen book chapters. He was appointed by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to advise Congress on the safety and efficacy of intravenous gamma globulin products. Dr. Jordan has been principal investigator on 3 NIH Controlled Clinical Trials in Kidney Transplantation. He has received the Medical Sciences Award from the UCLA Alumni Association, Gift of Life Award from the National Kidney Foundation, Established Investigator Award from the American Society of Transplantation, Distinguished Alumni Award from the University of North Carolina-Chapel Hill School of Medicine and the inaugural PRISM Award from Cedars-Sinai for excellences in clinical research. Dr. Jordan is a member of national and international professional societies and has served on the editorial boards of numerous professional journals, he is also a member of Hansa Medical’s Medical Advisory Board About IdeS IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS aims to degrade immunoglobulin G (IgG) and has been tested for safety and efficacy in numerous in vitro and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favourable safety profile. During 2014, a Phase II study in 8 sensitized patients awaiting kidney transplantation was conducted. Preliminary data show that IdeS is effective in reducing anti-HLA antibody levels in highly sensitized patients on the kidney transplant waitlist. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation. In addition to transplantation, IdeS has potential applications in a variety of rare autoimmune diseases. IdeS is protected by several patents and results of studies with IdeS have been published in a number of peer reviewed medical and scientific journals. About Hansa Medical AB Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq Stockholm’s main list with Remium Nordic AB as Certified Adviser.
Data shows that one dose of IdeS has favorable effect and
Top 10 Most Recent News Articles
Cultural Tech Fusion: The Asia-Pacific Way Forward
A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...
Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
Novo's Semaglutide Shows Promise in MASH Study
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
LG's ASIL D Certification: A Game Changer in Autos
Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...
Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings
The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...
Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise
Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...
Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue ReadingTop 5 Most Recently Viewed Articles
Palantir Technologies: Navigating Market Challenges Ahead
Palantir Technologies: An Overview of Current Stock Trends Palantir Technologies (NASDAQ: PLTR) has recently experienced fluctuations in its stock prices, especially after being announced as a new member of the NASDAQ 100. In the days following this announcement, investors observed a pullback of more than 5%, which can be closely tied to broader market trends influenced...
Continue Reading
Flood Coverage: Gaps in Home Insurance to Watch
Ask any homeowner in Westchester County about insurance, and you'll hear the same buzzword—flood. Sure, it's a tranquil spot to call home, but the insurance maze here can leave folks scratching their heads. When it rains cats and dogs, will your standard policy bail you out? Spoiler alert: Absolutely not. The Ins and Outs of Home Insurance Homeowners insurance isn't...
Continue Reading
Exploring the Impact of Food Apps on Brand Loyalty Dynamics
The Influence of Food Ordering Apps on Brand Loyalty In our increasingly digital world, the way we connect with brands has transformed dramatically. One striking example of this is the rise of food ordering apps. It's common for many of us to bypass dining out in favor of the convenience offered by services like DoorDash and Uber Eats. In fact, recent studies highlight...
Continue Reading
The Trimer Acid Market: Growth, Trends, and Future Prospects
Understanding the Growth of the Trimer Acid Industry The trimer acid industry has been on a remarkable growth journey as sectors globally pivot towards viable and sustainable materials. Known primarily for its role in the production of adhesives, sealants, coatings, and polyamide resins, trimer acid demonstrates versatility that appeals to various industries such as...
Continue Reading
Exploring Investment Strategies During Economic Uncertainty
Navigating Investment Strategies in Changing Times As the investment environment shifts, many investors are evaluating where to place their money to achieve the best returns. With tech stocks, particularly those dubbed the Magnificent Seven, facing ups and downs, an increasing number of investors are exploring traditional investment options that are known for their...
Continue Reading